Donate to MAPS' Phase 3 Studies of MDMA-Assisted Psychotherapy for PTSD in Europe
We have nearly completed funding our Phase 3 trials for FDA approval in the U.S. of MDMA-assisted psychotherapy for the treatment of PTSD. However, MAPS still needs approximately $5 million to conduct Phase 3 studies in Europe and seek regulatory approval from the European Medicines Agency (EMA). We aim to make MDMA-assisted psychotheray a legal treatment by 2021 in both the U.S. and Europe.
If you have a MAPS account, please log in HERE and your contact information will be filled in automatically.
If you would like to make a MAPS account, which will enable you to update your address and payment information, view your donation history, and more, please create a login name and password:
We are a 501(c)(3) non-profit research and educational organization developing medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.
Watch videos from Psychedelic Science 2017.
Explore recent news.